$CYCA
CYTTA CORP.

2023 Q3 Form 10-Q Financial Statement

#000147793223006321 Filed on August 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $8.120K $8.117K $936.00
YoY Change 147.56% 767.2%
Cost Of Revenue $0.00
YoY Change
Gross Profit $936.00
YoY Change
Gross Profit Margin 100.0%
Selling, General & Admin $1.597M $1.266M $1.163M
YoY Change 30.13% 8.83% 87.68%
% of Gross Profit 124297.01%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $10.88K $10.91K $11.90K
YoY Change -8.65% -8.36% 7.7%
% of Gross Profit 1271.69%
Operating Expenses $1.608M $1.277M $1.175M
YoY Change 29.76% 8.66% 93.41%
Operating Profit -$1.269M -$1.174M
YoY Change 8.05% 93.26%
Interest Expense -$61.72K $7.793K $22.00
YoY Change -28154.55% 35322.73% -75.28%
% of Operating Profit
Other Income/Expense, Net $34.05K $22.00
YoY Change 154654.55% -99.82%
Pretax Income -$1.661M -$1.303M -$1.174M
YoY Change 34.47% 10.95% 93.23%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.661M -$1.303M -$1.174M
YoY Change 34.47% 10.95% 93.23%
Net Earnings / Revenue -20461.08% -16052.94% -125470.73%
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00 -$3.113K
COMMON SHARES
Basic Shares Outstanding 418.4M shares 402.8M shares 377.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $674.8K $487.0K $1.569M
YoY Change -10.63% -68.97% 203.42%
Cash & Equivalents $674.8K $487.0K $1.569M
Short-Term Investments
Other Short-Term Assets $987.0K $115.4K $146.4K
YoY Change 2899.94% -21.19% -86.24%
Inventory $0.00 $0.00
Prepaid Expenses $987.0K $115.4K $146.4K
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $1.662M $602.4K $1.716M
YoY Change 110.88% -64.89% 1.92%
LONG-TERM ASSETS
Property, Plant & Equipment $77.56K $88.44K $134.9K
YoY Change -36.94% -34.44% -23.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $561.8K
YoY Change
Total Long-Term Assets $639.3K $88.44K $134.9K
YoY Change 419.83% -34.44% -23.36%
TOTAL ASSETS
Total Short-Term Assets $1.662M $602.4K $1.716M
Total Long-Term Assets $639.3K $88.44K $134.9K
Total Assets $2.301M $690.8K $1.851M
YoY Change 152.59% -62.67% -0.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.319M $1.136M $140.1K
YoY Change 631.04% 710.56% 270.82%
Accrued Expenses
YoY Change
Deferred Revenue $780.00
YoY Change
Short-Term Debt $40.00K $40.00K $0.00
YoY Change
Long-Term Debt Due $610.0K
YoY Change
Total Short-Term Liabilities $2.561M $1.830M $475.9K
YoY Change 470.21% 284.47% 414.28%
LONG-TERM LIABILITIES
Long-Term Debt $1.167M $35.66K $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.167M $35.66K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.561M $1.830M $475.9K
Total Long-Term Liabilities $1.167M $35.66K $0.00
Total Liabilities $2.561M $1.865M $475.9K
YoY Change 470.21% 291.96% 414.28%
SHAREHOLDERS EQUITY
Retained Earnings -$32.60M -$30.94M -$26.64M
YoY Change 16.96% 16.15%
Common Stock $426.8K $403.1K $377.6K
YoY Change 12.39% 6.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$260.4K -$1.174M $1.375M
YoY Change
Total Liabilities & Shareholders Equity $2.301M $690.8K $1.851M
YoY Change 152.59% -62.67% -0.47%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$1.661M -$1.303M -$1.174M
YoY Change 34.47% 10.95% 93.23%
Depreciation, Depletion And Amortization $10.88K $10.91K $11.90K
YoY Change -8.65% -8.36% 7.7%
Cash From Operating Activities -$317.2K -$277.2K -$571.1K
YoY Change -61.04% -51.47% 93.91%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 505.0K 550.0K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -317.2K -277.2K -571.1K
Cash From Investing Activities 0.000
Cash From Financing Activities 505.0K 550.0K 0.000
Net Change In Cash 187.8K 272.8K -571.1K
YoY Change -123.06% -147.77% -184335.48%
FREE CASH FLOW
Cash From Operating Activities -$317.2K -$277.2K -$571.1K
Capital Expenditures $0.00
Free Cash Flow -$571.1K
YoY Change 114.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 cyca Consulting Agreement
ConsultingAgreement
P1Y
CY2023Q1 cyca Consulting Agreement
ConsultingAgreement
P3Y
CY2023Q1 cyca Vesting Period
VestingPeriod
P2Y
CY2023Q1 cyca Vesting Period
VestingPeriod
P2Y
CY2023Q1 cyca Amortization Of Stock Option Agreement
AmortizationOfStockOptionAgreement
P3Y
CY2023Q1 cyca Amortization Of Stock Option Agreement
AmortizationOfStockOptionAgreement
P1Y
CY2023Q2 us-gaap Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
2000000 shares
dei Document Type
DocumentType
10-Q
CY2023Q1 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
1.00
us-gaap Professional Fees
ProfessionalFees
10000 usd
CY2022Q3 cyca Common Stock Par Or Stated Value Per Share1
CommonStockParOrStatedValuePerShare1
0.001
cyca Stock Based Compensation Expensed Related Party
StockBasedCompensationExpensedRelatedParty
10000 usd
cyca Stock Based Compensation Expensed
StockBasedCompensationExpensed
88825 usd
CY2023Q1 cyca Stock Value Issued For Services
StockValueIssuedForServices
275300 usd
cyca Stock Value Issued For Services
StockValueIssuedForServices
682575 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
400000 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001383088
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
403103420 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
379760670 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.025
CY2023Q1 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
1.00
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-257458
dei Entity Registrant Name
EntityRegistrantName
CYTTA CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0505761
dei Entity Address Address Line1
EntityAddressAddressLine1
5450 W Sahara Ave Suite 300A
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89146
dei City Area Code
CityAreaCode
702
dei Local Phone Number
LocalPhoneNumber
900-7022
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
418353420 shares
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
487018 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
755122 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
115377 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
32897 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
602395 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
788019 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
88440 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
122990 usd
CY2023Q2 us-gaap Assets
Assets
690835 usd
CY2022Q3 us-gaap Assets
Assets
911009 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
677105 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
180633 usd
CY2023Q2 us-gaap Related Party Deposit Liabilities
RelatedPartyDepositLiabilities
458453 usd
CY2022Q3 us-gaap Related Party Deposit Liabilities
RelatedPartyDepositLiabilities
180407 usd
CY2023Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
33427 usd
CY2022Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
33427 usd
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10528 usd
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
40000 usd
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
0 usd
CY2023Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
610000 usd
CY2022Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 usd
CY2023Q2 cyca Stock To Be Issued
StockToBeIssued
0 usd
CY2022Q3 cyca Stock To Be Issued
StockToBeIssued
54750 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1829513 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
449217 usd
CY2023Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
35660 usd
CY2022Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
0 usd
CY2023Q2 us-gaap Liabilities
Liabilities
1865173 usd
CY2022Q3 us-gaap Liabilities
Liabilities
449217 usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
403103420 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
379760670 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
403104 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
379761 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
29363951 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27956388 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-30942043 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27875007 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1174338 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
461792 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
690835 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
911009 usd
CY2023Q2 us-gaap Revenues
Revenues
8117 usd
CY2022Q2 us-gaap Revenues
Revenues
936 usd
us-gaap Revenues
Revenues
21941 usd
us-gaap Revenues
Revenues
2809 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
414008 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
216932 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
817492 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
895078 usd
CY2023Q2 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
863080 usd
CY2022Q2 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
958388 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
2226160 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
2924096 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1277088 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
1175320 usd
us-gaap Operating Expenses
OperatingExpenses
3043652 usd
us-gaap Operating Expenses
OperatingExpenses
3819174 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1268971 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1174384 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3021711 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3816365 usd
CY2023Q2 us-gaap Interest Expense Other
InterestExpenseOther
34141 usd
CY2022Q2 us-gaap Interest Expense Other
InterestExpenseOther
687 usd
us-gaap Interest Expense Other
InterestExpenseOther
45475 usd
us-gaap Interest Expense Other
InterestExpenseOther
48822 usd
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
95 usd
CY2022Q2 us-gaap Interest Income Other
InterestIncomeOther
665 usd
us-gaap Interest Income Other
InterestIncomeOther
150 usd
us-gaap Interest Income Other
InterestIncomeOther
665 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
34046 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
45325 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
48157 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1303017 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1174406 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3067036 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3864522 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1303017 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1174406 usd
us-gaap Net Income Loss
NetIncomeLoss
-3067036 usd
us-gaap Net Income Loss
NetIncomeLoss
-3864522 usd
CY2023Q2 cyca Basic And Diluted Earnings Per Share Basic And Diluted
BasicAndDilutedEarningsPerShareBasicAndDiluted
-0.00
CY2022Q2 cyca Basic And Diluted Earnings Per Share Basic And Diluted
BasicAndDilutedEarningsPerShareBasicAndDiluted
-0.00
cyca Basic And Diluted Earnings Per Share Basic And Diluted
BasicAndDilutedEarningsPerShareBasicAndDiluted
-0.01
cyca Basic And Diluted Earnings Per Share Basic And Diluted
BasicAndDilutedEarningsPerShareBasicAndDiluted
-0.01
CY2023Q2 cyca Weighted Average Shares Outstanding Basic And Diluted
WeightedAverageSharesOutstandingBasicAndDiluted
398546509 shares
CY2022Q2 cyca Weighted Average Shares Outstanding Basic And Diluted
WeightedAverageSharesOutstandingBasicAndDiluted
377276830 shares
cyca Weighted Average Shares Outstanding Basic And Diluted
WeightedAverageSharesOutstandingBasicAndDiluted
388748600 shares
cyca Weighted Average Shares Outstanding Basic And Diluted
WeightedAverageSharesOutstandingBasicAndDiluted
351337053 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
461792 usd
CY2022Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
407275 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-1100708 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-231641 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
275300 usd
CY2023Q1 cyca Common Stock Issued For Accounts Payable Amount
CommonStockIssuedForAccountsPayableAmount
39375 usd
CY2023Q1 cyca Common Stock Issued For Stock Payable Amount
CommonStockIssuedForStockPayableAmount
54750 usd
CY2023Q1 cyca Common Stock Issued For Accrued Liabilities Related Party Amount
CommonStockIssuedForAccruedLiabilitiesRelatedPartyAmount
55393 usd
CY2023Q1 cyca Common Stock And Warrants Issued For Cash Amount
CommonStockAndWarrantsIssuedForCashAmount
100000 usd
CY2023Q1 cyca Warrants Issued In Conjunction With Notes Payable
WarrantsIssuedInConjunctionWithNotesPayable
87001 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-663311 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-283133 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
400000 usd
CY2023Q2 cyca Common Stock Issued For Accounts Payable Amount
CommonStockIssuedForAccountsPayableAmount
11812 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1303017 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1174338 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
866244 usd
CY2021Q4 cyca Series F Preferred Stock Issued For Cash Amount
SeriesFPreferredStockIssuedForCashAmount
2963500 usd
CY2021Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
859100 usd
CY2021Q4 cyca Common Stock Issued For Accounts Payable Amount
CommonStockIssuedForAccountsPayableAmount
300000 usd
CY2021Q4 cyca Common Stock Issued For Conversion Of Series E Preferred Stock Amount
CommonStockIssuedForConversionOfSeriesEPreferredStockAmount
0 usd
CY2021Q4 cyca Common Stock Issued For Conversion Of Series F Preferred Stock Amount
CommonStockIssuedForConversionOfSeriesFPreferredStockAmount
0 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-1164106 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3824738 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
122075 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1526010 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2420803 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
128400 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1174406 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1374797 usd
us-gaap Profit Loss
ProfitLoss
-3067036 usd
us-gaap Profit Loss
ProfitLoss
-3864522 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1876993 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1850850 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
22661 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 usd
us-gaap Depreciation
Depreciation
34550 usd
us-gaap Depreciation
Depreciation
35711 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
78765 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
27694 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-82481 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
20966 usd
cyca Increase Decrease In Vendor Deposits
IncreaseDecreaseInVendorDeposits
0 usd
cyca Increase Decrease In Vendor Deposits
IncreaseDecreaseInVendorDeposits
50400 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
40391 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
94040 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
46290 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
129181 usd
cyca Increase Decrease In Dividend Payable
IncreaseDecreaseInDividendPayable
0 usd
cyca Increase Decrease In Dividend Payable
IncreaseDecreaseInDividendPayable
12394 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10528 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2808 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1118104 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1567329 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
100000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2963500 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
40000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
610000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
100000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
850000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2963500 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-268104 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1396171 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
755122 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
173196 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
487018 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1569367 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
cyca Issuance Of Common Stock For Accounts Payable And Accrued Liabilities
IssuanceOfCommonStockForAccountsPayableAndAccruedLiabilities
37200 usd
cyca Issuance Of Common Stock For Accounts Payable And Accrued Liabilities
IssuanceOfCommonStockForAccountsPayableAndAccruedLiabilities
300000 usd
cyca Issuance Of Common Stock For Accrued Expenses Related Party
IssuanceOfCommonStockForAccruedExpensesRelatedParty
55393 usd
cyca Issuance Of Common Stock For Accrued Expenses Related Party
IssuanceOfCommonStockForAccruedExpensesRelatedParty
0 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-30942043 usd
CY2022Q3 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
122990 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates.</p>
CY2023Q2 cyca Prepaid Expenses Beginning Balance
PrepaidExpensesBeginningBalance
32897 usd
CY2022Q2 cyca Prepaid Expenses Beginning Balance
PrepaidExpensesBeginningBalance
772394 usd
CY2023Q2 cyca Value Of Common Stock Issued
ValueOfCommonStockIssued
0 usd
CY2022Q2 cyca Value Of Common Stock Issued
ValueOfCommonStockIssued
894841 usd
CY2023Q2 cyca Amortization Of Stock Based Compensation
AmortizationOfStockBasedCompensation
0 usd
CY2022Q2 cyca Amortization Of Stock Based Compensation
AmortizationOfStockBasedCompensation
-1499874 usd
CY2023Q2 cyca Prepaid Expense From Other Activity
PrepaidExpenseFromOtherActivity
82480 usd
CY2022Q2 cyca Prepaid Expense From Other Activity
PrepaidExpenseFromOtherActivity
-20966 usd
CY2023Q2 cyca Prepaid Expenses Ending Balance
PrepaidExpensesEndingBalance
115377 usd
CY2022Q2 cyca Prepaid Expenses Ending Balance
PrepaidExpensesEndingBalance
146395 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
0 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
0 usd
CY2023Q2 us-gaap Depreciation
Depreciation
10908 usd
us-gaap Depreciation
Depreciation
34550 usd
CY2022Q2 us-gaap Depreciation
Depreciation
11903 usd
us-gaap Depreciation
Depreciation
35711 usd
CY2023Q2 cyca Commonstockissuedforpaymentof Acoountpayable Share
CommonstockissuedforpaymentofAcoountpayableShare
750000 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and cash equivalents and related party payables it will likely incur in the near future. The Company places its cash and cash equivalents with financial institutions of high credit worthiness. At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits. The Company’s management plans to assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.</p>
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
230900 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
230900 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
142460 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
107910 usd
CY2023Q2 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
88440 usd
CY2020Q4 cyca Annual Lease Payment Related Party
AnnualLeasePaymentRelatedParty
50000 usd
CY2023Q2 cyca Accounts Payables Related Parties Current
AccountsPayablesRelatedPartiesCurrent
458453 usd
CY2022Q3 cyca Accounts Payables Related Parties Current
AccountsPayablesRelatedPartiesCurrent
180407 usd
CY2023Q2 cyca Accounts Payables Related Parties Current
AccountsPayablesRelatedPartiesCurrent
458453 usd
CY2022Q3 cyca Accounts Payables Related Parties Current
AccountsPayablesRelatedPartiesCurrent
180407 usd
CY2023Q1 cyca Promissory Note Face Value
PromissoryNoteFaceValue
40000 usd
CY2023Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1000000 usd
CY2023Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2024-01-10
CY2023Q1 us-gaap Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
2000000 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.025
CY2023Q1 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
1.00
CY2023Q1 us-gaap Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
2000000 shares
us-gaap Short Term Debt Interest Rate Increase
ShortTermDebtInterestRateIncrease
0.18 pure
CY2023Q2 cyca Convertible Promissory Notes Payable
ConvertiblePromissoryNotesPayable
17087 usd
CY2023Q2 us-gaap Notes Payable
NotesPayable
645660 usd
CY2023Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
35660 usd
CY2023Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
610000 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 cyca Common Stock Par Or Stated Value Per Share1
CommonStockParOrStatedValuePerShare1
0.001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
403103420 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
379760670 shares
cyca Shares Issued For Services
SharesIssuedForServices
17750000 shares
CY2023Q2 cyca Common Stock Amount
CommonStockAmount
1082575 usd
CY2023Q2 cyca Commonstockissuedforpaymentof Acoountpayable
CommonstockissuedforpaymentofAcoountpayable
30000 shares
CY2023Q2 cyca Commonstock Issued Settlement Of Stock Payable
CommonstockIssuedSettlementOfStockPayable
39375 shares
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
9375 usd
us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
7200 usd
CY2023Q2 cyca Common Stock Outstanding Shares
CommonStockOutstandingShares
11812 shares
CY2023Q2 us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
4612 usd
CY2023Q2 cyca Common Stock Shares To Be Issued
CommonStockSharesToBeIssued
323583 usd
cyca Common Stock Issued
CommonStockIssued
4000000 shares
cyca Reduction In Capital Stcok To Be Issued
ReductionInCapitalStcokToBeIssued
268833 usd
CY2023Q2 cyca Capital Stock To Be Issued
CapitalStockToBeIssued
0 usd
CY2022Q3 cyca Capital Stock To Be Issued
CapitalStockToBeIssued
54750 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
10000000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
0.02
CY2023Q1 cyca Vesting Percentage
VestingPercentage
0.25 pure
CY2023Q1 cyca Stock Option Value
StockOptionValue
639543 usd
CY2023Q2 cyca Stock Based Compensation Expensed
StockBasedCompensationExpensed
53295 usd
CY2023Q1 cyca Stock Based Compensation Expensed
StockBasedCompensationExpensed
88825 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
10000000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
0.02
CY2023Q1 cyca Vesting Percentage
VestingPercentage
0.25 pure
CY2023Q1 cyca Stock Option Value
StockOptionValue
449651 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
20000000 shares
cyca Share Based Compensation Arrangements By Share Based Payment Award Options Issued In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsIssuedInPeriodWeightedAverageExercisePrice
0.02
cyca Weighted Average Remaining Term In Years Issued
WeightedAverageRemainingTermInYearsIssued
P2Y4M13D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20000000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y3D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
0 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0
CY2023Q2 us-gaap Interest Expense
InterestExpense
7793 usd
us-gaap Interest Expense
InterestExpense
11989 usd
CY2023Q1 cyca Purchase Of Warrant Common Stock Value
PurchaseOfWarrantCommonStockValue
449651 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
112413 usd
us-gaap Share Based Compensation
ShareBasedCompensation
149884 usd
CY2023Q2 us-gaap Share Price
SharePrice
0.04
CY2023Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
8994000 usd
CY2022Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
7804000 usd
cyca Software Products
SoftwareProducts
32470 usd
CY2023Q2 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
8117 usd
us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
21941 usd
CY2022Q2 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
936 usd
us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
2809 usd
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
10528 usd

Files In Submission

Name View Source Status
cyca-20230630_cal.xml Edgar Link unprocessable
0001477932-23-006321-index-headers.html Edgar Link pending
0001477932-23-006321-index.html Edgar Link pending
0001477932-23-006321.txt Edgar Link pending
0001477932-23-006321-xbrl.zip Edgar Link pending
cyca-20230630.xsd Edgar Link pending
cyca_10q.htm Edgar Link pending
cyca_ex311.htm Edgar Link pending
cyca_ex312.htm Edgar Link pending
cyca_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
cyca-20230630_def.xml Edgar Link unprocessable
cyca-20230630_pre.xml Edgar Link unprocessable
cyca-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cyca_10q_htm.xml Edgar Link completed
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending